HIGH GRADE SEROUS ADENOCARCINOMA OF OVARY
Clinical trials for HIGH GRADE SEROUS ADENOCARCINOMA OF OVARY explained in plain language.
Never miss a new study
Get alerted when new HIGH GRADE SEROUS ADENOCARCINOMA OF OVARY trials appear
Sign up with your email to follow new studies for HIGH GRADE SEROUS ADENOCARCINOMA OF OVARY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New immunotherapy cocktail targets tough cancers in early trial
Disease control OngoingThis early-phase study tests a new drug called AI-061, which combines two immunotherapy agents (anti-PD-1 and anti-CTLA-4) into one treatment. The goal is to find the safest dose and see if it can shrink tumors in people with advanced cancers like melanoma, lung, and ovarian canc…
Matched conditions: HIGH GRADE SEROUS ADENOCARCINOMA OF OVARY
Phase: PHASE1 • Sponsor: OncoC4, Inc. • Aim: Disease control
Last updated May 26, 2026 09:06 UTC
-
New hope for tough ovarian cancer: drug combo trial launches
Disease control OngoingThis study tests a combination of two drugs, ONC-392 and pembrolizumab, in 58 women with ovarian cancer that has stopped responding to platinum-based chemotherapy. The goal is to see if the combo can shrink tumors and control the disease. Participants must have a specific type of…
Matched conditions: HIGH GRADE SEROUS ADENOCARCINOMA OF OVARY
Phase: PHASE2 • Sponsor: OncoC4, Inc. • Aim: Disease control
Last updated May 26, 2026 09:03 UTC
-
New hope for recurrent gynaecological cancers: first human trial of IMGN151 begins
Disease control OngoingThis early-phase trial tests a new drug called IMGN151 in adults with certain gynaecological cancers that have come back. The study aims to find a safe dose and check for side effects. About 256 participants with recurrent endometrial, ovarian, fallopian tube, primary peritoneal,…
Matched conditions: HIGH GRADE SEROUS ADENOCARCINOMA OF OVARY
Phase: PHASE1 • Sponsor: AbbVie • Aim: Disease control
Last updated May 26, 2026 08:34 UTC
-
New pill shows promise for tough ovarian cancer
Disease control OngoingThis study tests a new oral drug called sovilnesib in people with advanced high-grade serous ovarian cancer that no longer responds to platinum chemotherapy. The main goal is to find the best dose that is safe and effective. About 120 adults will take the pill daily, and research…
Matched conditions: HIGH GRADE SEROUS ADENOCARCINOMA OF OVARY
Phase: PHASE1 • Sponsor: Volastra Therapeutics, Inc. • Aim: Disease control
Last updated May 22, 2026 13:55 UTC